Molecular and Cellular Biology, April 1999, p. 3029-3038, Vol. 19, No. 4
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
A Novel Ubiquitin-Specific Protease, UBP43, Cloned from Leukemia
Fusion Protein AML1-ETO-Expressing Mice, Functions in Hematopoietic
Cell Differentiation
Li-Qin
Liu,1
Robert
Ilaria Jr.,2,
Paul D.
Kingsley,3
Atsushi
Iwama,1
Richard A.
van
Etten,2
James
Palis,3 and
Dong-Er
Zhang1,*
Department of Medicine, Beth Israel Deaconess
Medical Center,1 and Center for Blood
Research,2 Harvard Medical School, Boston,
Massachusetts 02115, and Department of Pediatrics and
Cancer Center, University of Rochester, Rochester, New York
146423
Received 26 October 1998/Returned for modification 23 November
1998/Accepted 14 January 1999
 |
ABSTRACT |
Using PCR-coupled subtractive screening-representational difference
analysis, we have cloned a novel gene from AML1-ETO knockin mice.
This gene is highly expressed in the yolk sac and fetal liver of the
knockin mice. Nucleotide sequence analysis indicates that its cDNA
contains an 1,107-bp open reading frame encoding a 368-amino-acid
polypeptide. Further protein sequence and protein translation analysis
shows that it belongs to a family of ubiquitin-specific proteases
(UBP), and its molecular mass is 43 kDa. Therefore, we have named this
gene UBP43. Like other ubiquitin proteases, the UBP43
protein has deubiquitinating enzyme activity. Protein ubiquitination
has been implicated in many important cellular events. In wild-type
adult mice, UBP43 is highly expressed in the thymus and in
peritoneal macrophages. Among nine different murine
hematopoietic cell lines analyzed, UBP43 expression is detectable only in cell lines related to the monocytic lineage. Furthermore, its expression is regulated during cytokine-induced monocytic cell differentiation. We have investigated its
function in the hematopoietic myeloid cell line M1. UBP43 was
introduced into M1 cells by retroviral gene transfer, and several
high-expressing UBP43 clones were obtained for further study.
Morphologic and cell surface marker examination of UBP43/M1
cells reveals that overexpression of UBP43 blocks cytokine-induced
terminal differentiation of monocytic cells. These data suggest that
UBP43 plays an important role in hematopoiesis by modulating either the
ubiquitin-dependent proteolytic pathway or the ubiquitination state of
another regulatory factor(s) during myeloid cell differentiation.
 |
INTRODUCTION |
t(8;21) is associated with 15% of
de novo acute myelogenous leukemia cases and creates the AML1-ETO
fusion protein. AML1-ETO knockin mice have been generated to study
the effect of the leukemia-associated fusion protein AML1-ETO on
hematopoiesis and the pathogenesis of leukemia (34, 53).
AML1-ETO/+ embryos died between 11.5 and 13.5 days postcoitus (d.p.c.)
and exhibited severely disrupted hematopoiesis and hemorrhages
associated with the central nervous system. This phenotype is very
similar to that resulting from homozygous disruption of the AML1 gene
(35, 49), suggesting that AML1-ETO dominantly blocks normal
AML1 function during embryonic development. In contrast to AML1
knockout mice, which do not have any definitive hematopoiesis in the
yolk sac, cells isolated from the yolk sacs of AML1-ETO/+ 11.5-d.p.c.
embryos did give rise to macrophage-like colonies in vitro
(53), and cells isolated from the liver of AML1-ETO/+ 12.5- to 13.5-d.p.c. embryos showed dysplastic hematopoiesis
(34). These results suggest that AML1-ETO expression may
have other effects on hematopoiesis besides blocking wild-type AML1.
In this study, we employed representational difference analysis (RDA)
to identify genes differentially expressed in AML1-ETO knockin mice
and have isolated a novel gene, which belongs to a family of
ubiquitin-specific proteases (UBPs).
Ubiquitin is a 76-amino-acid (aa) polypeptide with a molecular mass of
8.5 kDa that was first isolated in 1975 from bovine thymus
(13). Ubiquitin is present in all eukaryotic cells and is
one of the most highly conserved proteins from humans to insects. Ubiquitin occurs in cells either in the free form or covalently coupled
via its carboxyl-terminal glycine residue to the
-amino groups of
lysine residues in a wide variety of intracellular proteins or of
Lys48 of another ubiquitin (1, 17).
Ubiquitination is an important protein modification. Two major groups
of enzymes, ubiquitin-conjugating enzymes and ubiquitin-specific
proteases (deubiquitinating enzymes), regulate the balance of protein
ubiquitination (20). Protein ubiquitination is important in
a variety of cellular events, one of which is ubiquitin-dependent
proteolysis. Proteolysis regulated by the ubiquitin pathway has been
implicated in control of the cell cycle (25), transcription
activation (48), and antigen presentation (41),
as well as in cell fate and growth (22, 54). In
ubiquitin-associated proteolysis, ubiquitin targets many critical
proteins, including p53 (5, 43), cyclins (12, 52), and the yeast MAT
2 repressor (2), for
proteolytic degradation by the proteasome. In addition to its important
role in proteasome-mediated proteolysis, protein ubiquitination has
other regulatory functions. It has been shown that histone
ubiquitination is increased in actively transcribing chromatin and
transformed cells (7, 29, 47). Ubiquitination also plays a
critical role in endocytosis of cell surface receptors (19)
and in activation of I
B
kinase (3).
There are two distinct families of deubiquitinating
enzymes
ubiquitin carboxyl-terminal hydrolases (UCHs) and
ubiquitin-processing proteases (UBPs). The enzymes of the UCH family
are small proteins that cleave ubiquitin from its relatively short
C-terminal extensions but that are virtually inactive with larger
protein substrates (27). The UBP enzymes are a group of
larger proteins that can cleave ubiquitin from a wide range of protein
substrates. While this family of enzymes shows little amino acid
sequence similarity, there are short consensus sequences surrounding
cysteine residues (Cys domain) and histidine residues (His domain) that
are highly conserved. These conserved domains are important in
generating the active site of the enzyme (6, 20). The high
degree of divergence in this large family of proteins implies that
different UBP family members may have unique biochemical properties,
substrate specificities, and cellular localizations. So far, little is
known about the function of protein ubiquitination in hematopoiesis. Here we report the cloning of UBP43, a novel member of the
ubiquitin-specific proteases, from AML1-ETO knockin mice.
UBP43 encodes a functional deubiquitinating enzyme. Its
expression is upregulated by AML1-ETO. The expression pattern of
UBP43 in normal adult mice and in hematopoietic cell lines
suggests that UBP43 may be involved in hematopoiesis. Furthermore, the
block of monocytic cell differentiation by constitutive expression of
UBP43 suggests an important role for this gene in hematopoiesis.
 |
MATERIALS AND METHODS |
RDA of cDNA and clone of UBP43 cDNA.
RDA of cDNA
was performed based on a protocol by Hubank and Schatz (23).
Generation of AML1-ETO knockin chimeric mice and production of the
germ line transmitted AML1-ETO knockin embryos have been reported
previously (53). Total RNA was isolated from yolk sacs of
both AML1-ETO knockin embryos and their wild-type littermates at
11.5 d.p.c. by guanidine isothiocyanate extraction and CsCl
gradient purification (4). Poly(A)+ RNA was
purified from total RNA with oligo(dT) cellulose columns (New England
Biolabs, Beverly, Mass.). cDNA was synthesized from 5 to 10 µg of
poly(A)+ RNA by using a cDNA synthesis kit according to the
manufacturer's instructions (GIBCO-BRL, Grand Island, N.Y.). cDNA
prepared from yolk sacs of AML1-ETO knockin embryos was used as a
tester, and cDNA prepared from control yolk sacs was used as a driver
in RDA. A partial cDNA fragment isolated by RDA was used as a probe to obtain full-length UBP43 cDNA from a mouse thymus cDNA
library. UBP43 cDNA was sequenced on both strands by the
dideoxy DNA sequencing method (U.S. Biochemicals, Cleveland, Ohio). The
cDNA sequence was confirmed by sequencing another UBP43
clone isolated from a murine macrophage library.
Assay for ubiquitin-specific protease activity.
The assay
for a ubiquitin-specific protease to deubiquitinate a
ubiquitin-
-galactosidase fusion protein has been previously described (38, 55). A plasmid expressing the glutathione
S-transferase (GST)-UBP43 fusion protein was constructed by
in-frame linkage of a murine UBP43 cDNA to plasmid pGEX-4T-3
(pBR322 Ampr replicon). Plasmid pAC-M-
-gal expresses the
Ub-Met-
-gal fusion protein substrate in a pACYC184 Cmr
replicon. Escherichia coli BL21 (DE3) bacteria harboring
pGEX-4T-3-UBP43 were transformed with pAC-M-
-gal,
Ampr Cmr colonies were grown and induced with
IPTG (isopropyl-
-D-thiogalactopyranoside), and total
protein extracts were analyzed by Western blotting with anti-
-galactosidase rabbit polyclonal antibody (Cappel, Aurora, Ohio) and by the enhanced chemiluminescence system (Amersham, Little
Chalfont, Buckinghamshire, England).
Northern blot analysis.
Total RNA was prepared from
different cell lines and mouse tissues by the guanidinium
isothiocyanate extraction method followed by cesium chloride gradient
purification. RNA (10 µg/lane) was denatured in
formamide-formaldehyde, followed by electrophoresis in 1%
agarose-formaldehyde gels. The RNA was then transferred to a positively
charged nylon membrane (ICN Biomedicals, Inc., Costa Mesa, Calif.). The
cDNA inserts, purified from low-melting-point agarose gels, were
radiolabeled by the random priming method and hybridized with membranes
in Church-Gilbert hybridization buffer (7% sodium dodecyl sulfate
[SDS] and 1% bovine serum albumin in 0.5 M NaPO4, pH
7.2) for at least 18 h at 65°C. The hybridized membranes were
washed in 1× SSC (0.15 M sodium chloride-0.015 M sodium citrate, pH
7.0) and 0.2% SDS at room temperature and then in 0.2× SSC and 0.1%
SDS at 65°C. Autoradiography was performed with Kodak XAR-5 film at
80°C.
In situ hybridization.
Embryos were dissected from the
peritoneum at 11.5 d.p.c., immediately placed in freshly prepared
ice-cold 4% paraformaldehyde in phosphate-buffered saline and fixed
overnight at 4°C. Then, the embryos were dehydrated through ethanol
into xylene, embedded in paraffin with a Tissue-Tek V.I.P. automatic
processor, and sectioned. The sections were dewaxed, rehydrated, and
treated with proteinase K to enhance probe accessibility and with
acetic anhydride to reduce nonspecific background. Single-stranded
33P-labeled antisense RNA probes were prepared by standard
techniques (30) with specific activities of 5 × 108 dpm/µg and hydrolyzed by alkaline treatment to
approximately 200 bp. The sense probe was synthesized to the same
specific activity as the antisense probe and served as a control for
nonspecific background. The sections were hybridized with
33P-labeled UBP43 antisense and sense
riboprobes, as described previously (37). Multiple embryos
and exposures of different lengths were examined for each sense and
antisense probe. Autoradiography with NTB-2 emulsion (Eastman Kodak,
Rochester, N.Y.) was performed for 7 to 28 days. Slides were developed
in D19 (Eastman Kodak), and the tissues were counterstained with
toluidine blue.
Cell culture and differentiation.
Murine monocytic cell
lines (RAW264.7 and M1), T-cell lines (BW5147 and EL4), B-cell lines
(Ba/F3 and 18.8), erythroid cell lines (MEL and 416B), and a
granulocytic cell line (32Dc13) were routinely grown in RPMI 1640 medium (BioWhittaker, Inc., Walkersville, Md.) containing 10% fetal
bovine serum (GIBCO-BRL) and 2 mM L-glutamine (GIBCO-BRL).
In addition, 10% WEHI3 conditioned medium (source of interleukin 3 [IL-3]) was added to the culture medium for Ba/F3 and 32Dc13 cells.
NIH 3T3 cells and 293T cells were grown in Dulbecco's modified Eagle
medium (BioWhittaker, Inc.) containing 10% fetal bovine serum and 2 mM
L-glutamine. All cells were cultured at 37°C under 5%
CO2. To induce macrophage differentiation, M1 cells were
cultured in the presence of recombinant human IL-6 (Amgen, Inc.,
Thousand Oaks, Calif.) at 100 ng/ml or leukemia inhibitory factor (LIF)
(GIBCO-BRL) at 50 ng/ml. To induce granulocyte differentiation, 32Dc13
cells were cultured in medium containing 500 units of granulocyte colony-stimulating factor (G-CSF) (Amgen, Inc.) in the absence of IL-3.
To check cell morphology, 104 cells were cytocentrifuged
onto each slide, stained with Wright-Giemsa solution, and examined
under a microscope.
Retrovirus production and infection.
The 1.4-kb
EcoRI-DraI murine UBP43 cDNA fragment
was inserted into the MSCVneo retroviral vector at
EcoRI/HpaI sites to form UBP43/MSCVneo
(16). This vector contains the Moloney murine leukemia virus
long terminal repeat to control expression of the inserted cDNA and the
simian virus 40 promoter to control expression of the selectable marker
neomycin phosphotransferase (neo) (32). Viruses were
generated from the recombinant retroviral vector (MSCVneo) or from the
UBP43 expression construct UBP43/MSCVneo, as
described previously (32). Briefly, 10 µg of
UBP43/MSCVneo or MSCVneo plasmid and 2 µg of
MSCVEcoPac packaging construct were cotransfected by the
Ca3(PO4)2 precipitation method into 293T cells. Forty-eight hours after transfection, the cell culture medium containing the produced viruses was collected and centrifuged at
800 × g for 10 min. The supernatant containing
retroviruses was passed through a 0.2-µm filter (Millipore, Bedford,
Mass.), aliquoted, and stored at
80°C. To infect cells,
107 CFU of neo retrovirus per ml were incubated with
107 M1 cells in the presence of polybrene (8 µg/ml)
(Sigma, St. Louis, Mo.) at 37°C for 12 h. Fresh medium was then
applied and the cells allowed recovering. Two days later, G418
(GIBCO-BRL) was added to the medium at 0.2 mg/ml for selection of
positively infected cells.
Nucleotide sequence accession number.
The DNA sequence of
murine UBP43 has been submitted to the GenBank database
under accession no. AF069502.
 |
RESULTS |
UBP43, a novel member of the ubiquitin-specific protease family,
was cloned from the yolk sac of AML1-ETO knockin mice.
As
reported previously, AML1-ETO knockin mice were generated to
evaluate the role of AML1-ETO in hematopoiesis (53). To identify genes whose expression is either directly or indirectly affected by AML1-ETO expression, we studied the change of gene expression in the yolk sac of knockin embryos by using PCR-coupled subtractive screening-RDA (23). Total RNA was prepared from the yolk sacs of both AML1-ETO knockin embryos and their wild-type littermates. Reverse transcription reactions were then performed to
generate cDNAs. To identify genes whose expression is upregulated by
AML1-ETO expression, cDNA from knockin mice was used as the tester
and cDNA from wild-type mice was used as the driver. After three rounds
of subtractive hybridization between tester cDNA and an excess amount
of driver cDNA, several cDNA fragments were obtained. Based on sequence
analysis, one of the cDNA fragments was from an unknown gene.
Subsequently, a 1,748-bp cDNA was isolated from a cDNA library by using
this fragment as a DNA probe. This cDNA contained an 1,107-bp open
reading frame encoding a polypeptide of 368 aa (Fig.
1). Comparison of the nucleotide sequence
of this gene to entries in the GenBank database revealed that it had no significant similarity to any previously sequenced genes. However, the
predicted amino acid sequence revealed a 20 to 25% similarity to
members of the ubiquitin-specific protease (UBP) family, including the
yeast proteins Ubp8, Ubp15 (20), and Doa4 (38);
human Tre-2 (36); and the mouse proteins Dub-1
(54) and Unp (15). The sequence similarity was
largely restricted to six conserved domains recently identified in all
UBP family members (51), including the Cys box, a
QQDAQEF motif, a region with the consensus sequence
LPQILVIHLKRF, and three blocks from the His box region (Fig.
2). The sequence alignments of the Cys
box and the His box between UBP43 and other indicated family members
gave the highest similarity. The putative active-site nucleophile is a
cysteine residue in the Cys box (38), found in all known
family members as well as in UBP43 (Cys61). Beyond the six conserved
regions, UBP43 has little homology to any known UBP43 family members or non-UBP proteins. Since the molecular mass calculated from the predicted 368 aa is approximately 43 kDa, as is the mass of its in
vitro-translated product (data not shown), we have named this novel
member of the UBP family UBP43.

View larger version (65K):
[in this window]
[in a new window]
|
FIG. 1.
Sequence of murine UBP43. The nucleotide
sequence was obtained from both strands by the dideoxy method. The
polyadenylation signal AATAAA is underlined. The deduced
amino acid sequence is shown below the nucleotide sequence.
|
|

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 2.
Sequence alignments of conserved domains between
UBP43 and selected members of the UBP family. Sequences
conserved among these proteins are shaded. The GenBank accession
numbers of these proteins are as follows: Dub-1, U41636; Unp, L00681;
Tre-2, X63547; Faf, P55824; Ubp8, P50102; Ubp15, P50101.
|
|
UBP43 encodes a functional ubiquitin-specific
protease.
In order to determine whether UBP43 has
ubiquitin-specific protease enzymatic activity, we expressed UBP43 as a
GST fusion protein in the expression vector pGEX-4T-3.
pGEX-4T-3-UBP43 was cotransformed into E. coli
BL21 (DE3) with a plasmid expressing the protein Ub-Met-
-gal, in
which ubiquitin is fused to the N terminus of
-galactosidase. As
shown by immunoblot analysis (Fig. 3),
four independent clones expressing the GST-UBP43 fusion protein demonstrated efficient cleavage of Ub-Met-
-gal (lanes 1, 2, 3, and
4), comparable to that observed with DUB-2, a known murine deubiquitinating enzyme (55) (lane 5). As expected, cells
with the pGEX-4T-3 vector (lane 6) failed to cleave Ub-Met-
-gal.
Therefore, the new member of deubiquitinating enzyme UBP family, UBP43,
has deubiquitinating enzyme activity.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 3.
UBP43 encodes a functional deubiquitinating
enzyme. A ubiquitin- -galactosidase (Ub-Met- -gal) fusion protein
expressed in bacteria was deubiquitinated. Shown is a Western blot with
anti- -galactosidase antiserum. Coexpressed plasmids were
pGEX-4T-3-UBP43 (lanes 1 to 4), the positive control
pGEX-DUB-2 (lane 5), and the negative control pGEX-4T-3 (vector) (lane
6).
|
|
UBP43 is highly expressed in the fetal hematopoietic
organs of AML1-ETO knockin embryos but not in AML1 knockout
embryos.
UBP43 was initially cloned by subtractive
hybridization screening of RNA from the yolk sacs of wild-type and
AML1-ETO knockin embryos. To further study the biological function
of UBP43, the pattern of its expression was compared between
knockin embryos and wild-type embryos. Total RNA was isolated from
11.5-d.p.c. whole embryo, yolk sac, blood, and brain of knockin and
wild-type mice and analyzed by Northern blotting. UBP43
was highly expressed in the yolk sacs of AML1-ETO knockin embryos
compared to those of wild-type embryos (Fig.
4A). A trace amount of UBP43
expression was also detected in wild-type yolk sacs. Furthermore,
UBP43 expression was also detected in whole embryos and
brain RNA of AML1-ETO knockin mice, although the level was much
lower than the expression level seen in the yolk sacs of knockin
mice. No UBP43 mRNA was detected in the blood of either
knockin or wild-type mice or in whole embryo proper and brain
tissue of wild-type mice. These results demonstrate that
UBP43 is abnormally upregulated in AML1-ETO-expressing mice, particularly in the yolk sac. Since the major phenotypes of AML1-ETO knockin and AML1 knockout mice are similar, UBP43
expression was also studied with RNA from yolk sacs of 11.5-d.p.c.
AML1 knockout embryos. No upregulation of UBP43 was
detected (Fig. 4B). To further study UBP43 expression in
AML1-ETO knockin mice, in situ hybridization analysis was performed
to examine the spatial pattern of UBP43 expression (Fig.
5). Both antisense strand and sense
strand riboprobes were used in the analysis. UBP43 was
highly expressed in the liver and yolk sac of 11.5-d.p.c. AML1-ETO
knockin embryos, with highest expression in the fetal liver. There
was also a lesser degree of UBP43 transcript accumulation in
much of the embryo proper, with differential accumulation in the
central nervous system. A more extensive temporal and spatial analysis
revealed no detectable UBP43 mRNA expression in 7.5-, 8.5-, 11.5-, and 12.5-d.p.c. wild-type embryos (Fig. 5 and data not shown).
Taken together, these results demonstrate that UBP43
expression is upregulated in midgestation AML1-ETO knockin mice,
particularly in the two fetal hematopoietic organs, yolk sac and liver.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 4.
UBP43 is highly expressed in the yolk sac of
AML1-ETO knockin mice. (A) Total RNA prepared from various tissues
of both wild-type (WT) and AML1-ETO knockin (KI) embryos at
11.5 d.p.c.; (B) total RNA prepared from the yolk sac of WT,
heterozygous (+/ ), and homozygous ( / ) AML1 knockout (KO) and
AML1-ETO KI embryos at 11.5 d.p.c. RNA samples (10 µg/lane) were
subjected to Northern blot analysis with 32P-labeled
UBP43 cDNA. Ethidium bromide-stained 28S rRNA is shown to
demonstrate equivalent RNA loading.
|
|

View larger version (107K):
[in this window]
[in a new window]
|
FIG. 5.
In situ hybridization analysis demonstrates high-level
UBP43 expression in two fetal hematopoietic organs, liver
and yolk sac, of AML1-ETO knockin mice. Both AML1-ETO knockin
and wild-type embryos at 11.5 d.p.c. were subjected to in situ
hybridization analysis with 33P-labeled UBP43
antisense and sense riboprobes. Shown are dark-field (left) and
light-field (right) views of wild-type embryo hybridized to
UBP43 antisense probe (A and B), AML1-ETO knockin embryo
hybridized to UBP43 antisense probe (C and D), and AML1-ETO
knockin embryo hybridized to UBP43 sense probe (E and
F).
|
|
Expression of UBP43 is restricted to monocytic cell
lines and several tissues.
As shown in Fig. 4 and 5,
UBP43 was expressed at extremely low levels during normal
embryogenesis. However, UBP43 was highly expressed in the
two fetal hematopoietic organs of AML1-ETO knockin mice that lack
normal hematopoiesis. To further characterize the potential function of
UBP43, we first analyzed its expression in various tissues of wild-type
adult mice. When total cellular RNA was used in Northern blot
hybridization, the highest level of UBP43 expression was
detected in the thymus (Fig. 6).
UBP43 was also highly expressed in peritoneal macrophages
collected from intraperitoneal thioglycolate-treated mice. A low, but
clearly detectable, level of UBP43 expression was also seen
in the bone marrow, as well as in adipose tissue and lung. We also
examined UBP43 expression in a variety of hematopoietic cell
lines of different lineages. These included T-cell lines (BW5147 and
EL4), B-cell lines (Ba/F3 and 18.8), an erythroid cell line (MEL), an
early myeloid cell line (416B), a granulocytic cell line (32Dc13), a monocyte/macrophage cell line (RAW 264.7), and a myeloblastic cell line
that can be differentiated to macrophage-like cells (M1).
UBP43 expression was detected only in the two
monocyte-related cell lines, RAW 264.7 and M1 (Fig.
7), suggesting that UBP43 may play an important role in the monocytic lineage.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 6.
Northern blot analysis of UBP43 expression in
different tissues of adult mice. Total RNA was prepared from different
tissues of wild-type adult mice as indicated at the top of the figure.
Samples (10 µg/lane) were subjected to Northern blot analysis with a
32P-labeled UBP43 cDNA probe. Ethidium
bromide-stained 28S rRNA is shown to demonstrate equivalent RNA
loading.
|
|

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 7.
UBP43 is highly expressed in monocytic cell
lines. Total RNAs from nine different murine hematopoietic cell lines
and one fibroblast-like cell line were used for Northern blot analysis.
BW5147 and EL4 are T-cell lines, Ba/F3 and 18.8 are B-cell lines, MEL
and 416B are erythroid cell lines, RAW 264.7 and M1 are monocytic cell
lines, 32D is a granulocytic cell line, and NIH 3T3 is a
fibroblast-like cell line. RNAs from brain and thymus were used as
negative and positive controls, respectively. Each lane was loaded with
10 µg of total RNA. The blot was hybridized with a
32P-labeled UBP43 cDNA probe. Ethidium
bromide-stained 18S rRNA is shown to demonstrate equivalent RNA
loading.
|
|
Expression of UBP43 is regulated during
cytokine-induced macrophage differentiation of M1 cells.
The M1
myeloblastic leukemia cell line was derived in vitro from a spontaneous
myeloblastic leukemia arising in SL strain mice (24). This
cell line proliferates autonomously and can be induced with IL-6 or LIF
to terminally differentiate along the macrophage lineage
(21). Having determined that UBP43 is expressed
in M1 cells (Fig. 7), we next studied whether there was any
change in UBP43 expression during M1 cell macrophage
differentiation. M1 cells were cultured in the presence or absence of
IL-6, and total RNA was extracted at various time points and analyzed
by Northern blotting. Expression of UBP43 peaked by day 1, gradually declined, and was eventually lost upon the induction of
terminal differentiation at day 3 (Fig.
8). Similar results were seen when cells
were treated with LIF (data not shown). The murine IL-3-dependent cell
line 32Dc13 can be induced towards granulocytic differentiation by
G-CSF (11, 46). Although UBP43 expression was not
detected in 32Dc13 cells (Fig. 7), we tested whether UBP43
expression could be induced during differentiation of 32Dc13 cell to
granulocytes by G-CSF. As shown in Fig. 8, RNA hybridization analysis
did not give any detectable UBP43 expression throughout the
entire differentiation of 32Dc13 cells to granulocytes by G-CSF. These
results indicate that UBP43 expression is lineage restricted
and is regulated during monocytic cell differentiation.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 8.
Expression of UBP43 is regulated during M1
cell differentiation toward macrophages. Total RNAs were isolated from
RAW264.7 cells (R); M1 cells cultured in the presence of 100 ng of IL-6
per ml for 0, 1, 2, and 3 days for macrophage differentiation; and
32Dc13 cells cultured in the presence of 500 units of G-CSF per ml for
granulocytic cell differentiation. Each lane was loaded with 10 µg of
total RNA. The blot was hybridized with a 32P-labeled
UBP43 cDNA probe. Ethidium bromide-stained 18S rRNA is shown
to demonstrate equivalent RNA loading.
|
|
Constitutive expression of UBP43 blocks terminal
differentiation of M1 cells.
To ascertain whether the observed
alteration of UBP43 expression during IL-6- or LIF-dependent
M1 cell differentiation was related to the process of differentiation,
stable cell lines constitutively expressing UBP43 were
established by retroviral infection and G418 selection. Polyclonal
populations of M1 cells expressing UBP43 and control
populations containing the retroviral vector alone were confirmed by
both Southern and Northern blot analysis (data not shown).
G418-resistant pools of infected cells were evaluated for morphological
evidence of macrophage differentiation and for the expression of F4/80,
a macrophage-specific marker, after 3 days in either IL-6 or LIF. Upon
IL-6 treatment, parental M1 cells and control M1 cells infected with
the vector alone (neo/M1) displayed the morphological features of
mature macrophages: abundant, heavily vacuolated cytoplasms; a reduced
nuclear to cytoplasmic ratio; distinct heterochromatin; and the lack of
prominent nucleoli (Fig. 9A). In
contrast, cells infected with the UBP43 retrovirus (UBP43/M1) either remained undifferentiated or displayed an
intermediate level of maturation (i.e., promonoblast) characterized by
minimal vacuolation, a high nuclear to cytoplasmic ratio, and prominent nucleoli (Fig. 9A), as described previously for the block of M1 cell
differentiation (8, 21). Similar morphological changes were
seen with treatment of UBP43/M1, neo/M1, and parental cells with LIF (data not shown). Furthermore, UBP43/M1 cells
failed to terminally differentiate even after 5 days in culture with IL-6 or LIF. Enumeration of the proportion of cell types within each
population upon IL-6 or LIF treatment is given in Table
1. Since UBP43/M1 cells were
less morphologically mature than parental M1 cells or control neo/M1
cells, they were evaluated for expression of the cell surface marker
F4/80, which is specific for macrophages (14). As shown by
flow cytometry analysis (Fig. 9B), control M1 cells (neo/M1) had a
significant increase in F4/80 expression upon IL-6-induced
differentiation. UBP43/M1 cells displayed only 20% F4/80
expression compared to control neo/M1 cells after 3 days of incubation
with IL-6 (Fig. 9B). We also analyzed expression of c-myc
and CD34 during IL-6-induced cell differentiation. As reported by other
groups (8, 21), CD34 was normally expressed in M1 cells and
its expression was decreased during M1 cell differentiation, while
c-myc expression was upregulated in day 1 and then
downregulated (see M1/IL6, 0 to 3 days, in Fig. 9C). However, M1 cells
with constitutive UBP43 expression showed disrupted gene
regulation (Fig. 9C). There was continuous expression of CD34 and
delayed upregulation of c-myc. These data are consistent
with the results from morphological analysis and indicate that
constitutive expression of UBP43 blocks the terminal
differentiation program of M1 cells, perhaps by disturbing the normal
variation of UBP43 expression during terminal macrophage
differentiation of M1 cells.


View larger version (103K):
[in this window]
[in a new window]
|
FIG. 9.
Constitutive expression of UBP43 in M1 cells
blocks terminal macrophage differentiation. (A) Morphological analysis.
After 3 days of culture in the absence or presence of IL-6, cells were
evaluated for morphological evidence of terminal differentiation. As
detected by Wright-Giemsa stain, the majority of parental M1 cells or
control M1 cells infected with retroviral vector alone (neo/M1) showed
the morphological features of mature macrophages: heavily vacuolated
cytoplasm, a reduced nuclei to cytoplasmic ratio, distinct
heterochromatin, and the lack of prominent nucleoli. In contrast, cells
overexpressing UBP43 (UBP43/M1) showed evidence
of arrested maturation, with most cells having the morphology of
promonoblasts or undifferentiated blasts.
UBP43-overexpressing cells that were not treated with IL-6
remained entirely undifferentiated, similar to parental and control
cells. (B) Flow cytometry analysis of F4/80 expression on IL-6 treated
control M1 cells (neo/M1) and UBP43-overexpressing M1 cells
(UBP43/M1) by using a phycoerythrin-conjugated monoclonal
antibody specific for F4/80. Results from representative clones are
shown. (C) Northern blot analysis of CD34 and c-myc
expression. Total RNA from M1, neo/M1, and UBP43/M1 clone 3 as well as
UBP43/M1 clone 4 cells cultured for the times indicated in the presence
of 100 ng of IL-6 per ml were prepared for analysis by Northern
blotting of the expression of c-myc and CD34. Each lane was
loaded with 10 µg of total RNA. The blot was hybridized with a
32P-labeled murine c-myc or murine CD34 cDNA
probe. Ethidium bromide-stained 28S rRNA is shown to demonstrate
equivalent RNA loading.
|
|
When cells are induced to terminal differentiation, they become growth
arrested. As expected, control M1 cells (neo/M1) became growth arrested
after 2 days of incubation with IL-6 or LIF (Fig. 10). Interestingly, M1 cells with
UBP43 overexpression (UBP43/M1) also showed
growth arrest after 2 days incubation with IL-6 or LIF (Fig. 10),
although their terminal differentiation was partially blocked. There
was no significant difference between the proliferation rates of neo/M1
cells and UBP43/M1 cells. This indicates that constitutive
expression of UBP43 does not affect the proliferation program of M1 cells.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 10.
Overexpression of UBP43 does not affect cell
proliferation. Cells (1.5 × 105) were seeded with or
without the appropriate treatment, and numbers of viable cells were
determined at the indicated times by hemocytometer count. Each time
point is the average of three independent experiments of each of the
three populations of M1 cells either carrying retrovirus vector alone
(neo/M1) or containing the UBP43-expressing retrovirus
construct (UBP43/M1).
|
|
 |
DISCUSSION |
The AML1-ETO chimeric protein is produced by t(8;21)(q22;q22),
which is one of the most frequent chromosomal abnormalities detected in
acute myelogenous leukemia (42). The AML1-ETO fusion protein
has been shown to function primarily as a transcriptional repressor of
AML1 target genes and to block AML1 function in vitro and in vivo
(10, 31, 34, 53). However, the fusion protein can also
activate the BCL-2 promoter and cooperate with AML1 to activate the
macrophage CSF (M-CSF) receptor promoter (26, 40). To
characterize the effect of AML1-ETO on hematopoiesis, we used RDA
to identify its target genes in AML1-ETO-expressing mice. A novel gene,
UBP43, has been isolated. It encodes a functional enzyme that belongs to the ubiquitin-specific protease family. UBP43 is highly expressed in the fetal liver and yolk sac of
AML1-ETO knockin mice but not in wild-type mice. In wild-type adult
mice, UBP43 expression is associated with hematopoietic
tissues
the thymus and peritoneal macrophages
further suggesting a
biological function of UBP43 in blood cells. The appropriate cell-type-
and stage-specific expression of UBP43 may play a critical
role in hematopoietic differentiation. Furthermore, we have shown that dysregulated overexpression of UBP43 in a myeloblastic cell
line blocks its terminal differentiation. Taken together, our results suggest an important role of UBP43 in hematopoiesis.
UBP43 could be a target gene of AML1-ETO or an upregulated
gene related to AML1-ETO expression. Recent experiments have also suggested a direct link between UBP43 gene expression and
AML1-ETO expression. We have generated transgenic mice that have
inducible AML1-ETO expression in the bone marrow and macrophages under
the control of tetracycline. Compared to littermates that did not express AML1-ETO, AML1-ETO-positive transgenic mice showed a higher level of UBP43 expression (18). There are several
possible pathways through which AML1-ETO may regulate
UBP43 expression: (i) the AML1-ETO fusion protein may
directly upregulate UBP43 expression; (ii) the AML1-ETO
fusion protein may block AML1 regulation and thereby result in the
upregulation of its target gene, UBP43, if AML1 is a
repressor for UBP43; (iii) the AML1-ETO fusion protein may mediate
other transcriptional activities, which in turn affect UBP43 gene expression. Further studies will be necessary to
better define the mechanism by which AML1-ETO upregulates
UBP43 expression.
It is apparent that the mechanisms of, and the balance between,
ubiquitination and deubiquitination are an important determinant in
ubiquitin-dependent cellular events. Just as protein ubiquitination is
mediated by ubiquitin-conjugating enzymes, protein deubiquitination is
mediated by deubiquitinating enzymes or ubiquitin-specific proteases
(UBPs). There are a large number of UBP family members present in
yeasts, animals, and plants (20). All UBP family members
have several highly homologous domains, but there is little similarity
among these members outside these domains. It has been postulated that
these variable regions are responsible for their substrate specificity
and their cellular localization. To fully understand the function of
UBP43, it will be very important to identify its biological substrates.
Coexpression of UBP fusion proteins and an artificial UBP substrate,
Ub-Met-
-gal, has been used to identify UBP enzyme activity. Most
UBPs, such as Dub-1 (54), Ubp1 (45), Doa4
(38), and UBP43 exhibit enzyme activity in this assay. The
presence of such a large family of UBP enzymes is indicative of
functional diversity. Recent evidence confirms that UBPs do in fact
play distinct roles in regulating biological processes including cell
growth and differentiation. For instance, the Drosophila
melanogaster UBP, Faf (fat facets), is involved in cell fate
determination (9); the mammalian Tre-2 oncoprotein, a member
of the UBP superfamily (38), acts normally as a growth suppressor within the cell; and yeast Ubp3 is linked to a chromatin regulatory process of transcriptional silencing (33). Here, we provide evidence to suggest an additional biological role for UBPs
in hematopoietic cell differentiation. Expression of a
leukemogenesis-related fusion protein, AML1-ETO, directly or indirectly
increased the level of UBP43 enzyme inappropriately. It is possible
that such an increase in enzyme activity blocks the normal
ubiquitination of UBP43-specific substrates. These substrates must be
normally degraded through the ubiquitination proteasome pathway for
differentiation to occur. This model, that UBP43 negatively regulates
the turnover of specific substrates of the ubiquitin pathway, adds
credence to the hypothesis explaining the reasons for the diversity and abundance of UBPs. This is consistent with genetic interactions observed between the fat facets mutations and proteasome mutations in
Drosophila (9).
The upregulation of UBP43 in two hematopoiesis-related
tissues in AML1-ETO-expressing embryos (Fig. 4 and 5), the dysplastic hematopoiesis in the yolk sac and liver of AML1-ETO-expressing embryos
(34, 52), and the enriched expression of UBP43 in the thymus and thioglycolate-stimulated macrophages of wild-type adult
mice (Fig. 6) all suggest a role for UBP43 in hematopoiesis. To investigate whether UBP43 is important in hematopoiesis,
we have studied its expression in hematopoietic cell lines of various lineages. Among the nine murine hematopoietic cell lines tested, UBP43 was expressed only in the monocyte-related cell lines
M1 and RAW264.7. Furthermore, expression of UBP43 was
regulated in IL-6- or LIF-induced macrophage differentiation in M1
cells. UBP43 expression was significantly increased during the first
day of IL-6 induction and decreased to below the basal level of
untreated M1 cells upon macrophage maturation. These data suggest that
regulated expression of UBP43 might be required for terminal
macrophage differentiation. To test this hypothesis, we constitutively
expressed UBP43 in M1 cells and found that constitutive
expression of UBP43 blocked terminal macrophage
differentiation in M1 cells. UBP43/M1 cells did not acquire a mature
macrophage phenotype, as judged by morphology; failed to express a
macrophage surface marker, F4/80; and lacked the ability to suppress
c-myc and CD34 expression upon IL-6 induction. Thus,
constitutive expression of UBP43 can contribute to a block
of terminal myeloid differentiation, one of the characteristics of
acute leukemia. Since UBP43 overexpression did not change cell
proliferation and cells become unhealthy after 3 days treatment with
IL-6 or LIF, it is possible that this "block of terminal
differentiation" is a delay of cell differentiation. The relationship
between leukemogenesis and UBP43 expression requires further investigation.
It has been postulated that, in general, terminal differentiation is
accompanied by cell growth arrest (39). M1 cells, when induced to terminal differentiation by IL-6 or LIF, exit the cell cycle
and become growth arrested (data not shown) (21).
Interestingly, in spite of a lack of terminal differentiation, M1 cells
overexpressing UBP43 still undergo growth arrest similar to
control cells, suggesting that UBP43 primarily interferes with a
differentiation process independent of cell cycle regulation. Distinct
regulation of differentiation and proliferation in the maturation
process has been suggested by others (44). Constitutive
expression of WT1 in U937 cells abrogates cell differentiation but is
still accompanied by cell accumulation in the
G1/G0 phase of the cell cycle. Overall, these data support the notion that AML1-ETO expression disrupts expression of
a number of genes, some of which may play important roles in cell
differentiation and others of which may be important for cell
proliferation. Abnormal expression of these genes may cooperate to
cause cell transformation.
Since UBP43 expression was initially increased upon IL-6
treatment, we also analyzed multiple cell lines from various tissue origins to examine whether this increase in UBP43 was due to IL-6 stimulation. Northern blot analysis with RNA prepared from these cells showed that UBP43 was not an IL-6-responsive gene
(data not shown). This indicates that the up- and downregulation of UBP43 in M1 cells is related to cell differentiation.
Currently, we do not know which cells in the thymus are positive for
UBP43 expression. However, the high level of UBP43 expression in the thymus suggest a possible link between UBP43 and immature T-cell apoptosis. Therefore, we also analyzed UBP43 expression in a mouse model with regulated thymocyte apoptosis (28). There were no observed changes in UBP43 expression in thymic RNA derived from either untreated mice or mice treated with anti-CD3
monoclonal antibody to induce thymocyte apoptosis (data not shown).
In summary, we have cloned a novel member of the UBP family, which has
a highly restricted tissue distribution in normal adult mice and is
highly expressed in the fetal hematopoietic organs of AML1-ETO
knockin mice. Most importantly, the experimental data suggest a
potential role of UBP43 in hematopoiesis. The cloning of the human
UBP43 gene and the study of its expression in normal tissues
and in leukemia cells and other cancer cells will provide important
information related to leukemogenesis and cancer biology in general. In
addition, the discovery of this new member of the UBP protein family
will facilitate our studies of protein ubiquitination in hematopoiesis
and cell differentiation.
 |
ACKNOWLEDGMENTS |
We thank Daniel Tenen and Stuart Orkin for many helpful
discussions and critical reading of the manuscript; Linda Clayton for
providing the murine thymus cDNA library; Christopher Hetherington, Donald Yergeau, Kathy Maltby, and Pu Zhang for technical help; Alan
D'Andrea for providing the substrate Ub-Met-
-gal; Nancy Speck for
providing AML1 knockout mice; and Marie-Thérèse Little for
editing the manuscript.
This work was supported by National Institutes of Health grants
CA/AI59589 (D.E.Z.), CA/72009 (D.E.Z.) and HL 59484-01 (J.P.); American
Cancer Society grant DHP-166 (D.E.Z.); and the Japan Research
Foundation for Clinical Pharmacology and a long-term fellowship from
the Human Frontier Science Program (A.I.). D.E.Z. is a Leukemia Society
of America Scholar.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: HIM 953, Harvard
Institutes of Medicine, 77 Avenue Louis Pasteur, Boston, MA 02115. Phone: (617) 667-8930. Fax: (617) 667-3299. E-mail:
dzhang{at}bidmc.harvard.edu.
Present address: Simmons Cancer Center, University of Texas
Southwestern Medical Center, Dallas, TX 75235.
 |
REFERENCES |
| 1.
|
Chau, V.,
J. W. Tobias,
A. Bachmair,
D. Marriott,
D. J. Ecker,
D. K. Gonda, and A. Varshavsky.
1989.
A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein.
Science
243:1576-1583[Abstract/Free Full Text].
|
| 2.
|
Chen, P.,
P. Johnson,
T. Sommer,
S. Jentsch, and M. Hochstrasser.
1993.
Multiple ubiquitin-conjugating enzymes participate in the in vivo degradation of the yeast MAT alpha 2 repressor.
Cell
74:357-369[Medline].
|
| 3.
|
Chen, Z. J.,
L. Parent, and T. Maniatis.
1996.
Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity.
Cell
84:853-862[Medline].
|
| 4.
|
Chirgwin, J. M.,
A. E. Przybyla,
R. J. MacDonald, and W. J. Rutter.
1979.
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.
Biochemistry
18:5294-5299[Medline].
|
| 5.
|
Chowdary, D. R.,
J. J. Dermody,
K. K. Jha, and H. L. Ozer.
1994.
Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway.
Mol. Cell. Biol.
14:1997-2003[Abstract/Free Full Text].
|
| 6.
|
D'Andrea, A., and D. Pellman.
1998.
Deubiquitinating enzymes: a new class of biological regulators.
Crit. Rev. Biochem. Mol. Biol.
33:337-352[Medline].
|
| 7.
|
Davie, J. R., and L. C. Murphy.
1990.
Level of ubiquitinated histone H2B in chromatin is coupled to ongoing transcription.
Biochemistry
29:4752-4757[Medline].
|
| 8.
|
Fackler, M. J.,
D. S. Krause,
O. M. Smith,
C. I. Civin, and W. S. May.
1995.
Full-length but not truncated CD34 inhibits hematopoietic cell differentiation of M1 cells.
Blood
85:3040-3047[Abstract/Free Full Text].
|
| 9.
|
Fischer-Vize, J. A.,
G. M. Rubin, and R. Lehmann.
1992.
The fat facets gene is required for Drosophila eye and embryo development.
Development
116:985-1000[Abstract].
|
| 10.
|
Frank, R.,
J. Zhang,
H. Uchida,
S. Meyers,
S. W. Hiebert, and S. D. Nimer.
1995.
The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.
Oncogene
11:2667-2674[Medline].
|
| 11.
|
Friedman, A. D.,
B. L. Krieder,
D. Venturelli, and G. Rovera.
1991.
Transcriptional regulation of two myeloid-specific genes, myeloperoxidase and lactoferrin, during differentiation of the murine cell line 32D C13.
Blood
78:2426-2432[Abstract/Free Full Text].
|
| 12.
|
Glotzer, M.,
A. W. Murray, and M. W. Kirschner.
1991.
Cyclin is degraded by the ubiquitin pathway.
Nature
349:132-138[Medline].
|
| 13.
|
Goldstein, G.,
M. Scheid,
U. Hammerling,
D. H. Schlesinger,
H. D. Niall, and E. A. Boyse.
1975.
Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells.
Proc. Natl. Acad. Sci. USA
72:11-15[Abstract/Free Full Text].
|
| 14.
|
Gordon, S.,
S. Keshav, and L. P. Chung.
1988.
Mononuclear phagocytes: tissue distribution and functional heterogeneity.
Curr. Opin. Immunol.
1:26-35[Medline].
|
| 15.
|
Gupta, K.,
M. Chevrette, and D. A. Gray.
1994.
The Unp proto-oncogene encodes a nuclear protein.
Oncogene
9:1729-1731[Medline].
|
| 16.
|
Hawley, R. G.,
F. H. Lieu,
A. Z. Fong, and T. S. Hawley.
1994.
Versatile retroviral vectors for potential use in gene therapy.
Gene Ther.
1:136-138[Medline].
|
| 17.
|
Hershko, A., and A. Ciechanover.
1992.
The ubiquitin system for protein degradation.
Annu. Rev. Biochem.
61:761-807[Medline].
|
| 18.
| Hetherington, C. J., N. Harakawa, D. A. Yergeau, L.-Q. Liu, D. G. Tenen, and D. E. Zhang. Inducible AML1-ETO expression in transgenic mice. Submitted
for publication.
|
| 19.
|
Hicke, L., and H. Riezman.
1996.
Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis.
Cell
84:277-287[Medline].
|
| 20.
|
Hochstrasser, M.
1996.
Ubiquitin-dependent protein degradation.
Annu. Rev. Genet.
30:405-439[Medline].
|
| 21.
|
Hoffman-Liebermann, B., and D. A. Liebermann.
1991.
Interleukin-6- and leukemia inhibitory factor-induced terminal differentiation of myeloid leukemia cells is blocked at an intermediate stage by constitutive c-myc.
Mol. Cell. Biol.
11:2375-2381[Abstract/Free Full Text].
|
| 22.
|
Huang, Y.,
R. T. Baker, and J. A. Fischer-Vize.
1995.
Control of cell fate by a deubiquitinating enzyme encoded by the fat facets gene.
Science
270:1828-1831[Abstract/Free Full Text].
|
| 23.
|
Hubank, M., and D. G. Schatz.
1994.
Identifying differences in mRNA expression by representational difference analysis of cDNA.
Nucleic Acids Res.
22:5640-5648[Abstract/Free Full Text].
|
| 24.
|
Ichikawa, Y.
1970.
Further studies on the differentiation of a cell line of myeloid leukemia.
J. Cell Physiol.
76:175-184[Medline].
|
| 25.
|
King, R. W.,
R. J. Deshaies,
J. M. Peters, and M. W. Kirschner.
1996.
How proteolysis drives the cell cycle.
Science
274:1652-1659[Abstract/Free Full Text].
|
| 26.
|
Klampfer, L.,
J. Zhang,
A. O. Zelenetz,
H. Uchida, and S. D. Nimer.
1996.
The AML1/ETO fusion protein activates transcription of BCL-2.
Proc. Natl. Acad. Sci. USA
93:14059-14064[Abstract/Free Full Text].
|
| 27.
|
Larsen, C. N.,
J. S. Price, and K. D. Wilkinson.
1996.
Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues.
Biochemistry
35:6735-6744[Medline].
|
| 28.
|
Lerner, A.,
L. K. Clayton,
E. Mizoguchi,
Y. Ghendler,
E. W. Van,
S. Koyasu,
A. K. Bhan, and E. L. Reinherz.
1996.
Cross-linking of T-cell receptors on double-positive thymocytes induces a cytokine-mediated stromal activation process linked to cell death.
EMBO J.
15:5876-5887[Medline].
|
| 29.
|
Levinger, L., and A. Varshavsky.
1982.
Selective arrangement of ubiquitinated and D1 protein-containing nucleosomes within the Drosophila genome.
Cell
28:375-385[Medline].
|
| 30.
|
Melton, D. A.,
P. A. Krieg,
M. R. Rebagliati,
T. Maniatis,
K. Zinn, and M. R. Green.
1984.
Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.
Nucleic Acids Res.
12:7035-7056[Abstract/Free Full Text].
|
| 31.
|
Meyers, S.,
N. Lenny, and S. W. Hiebert.
1995.
The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation.
Mol. Cell. Biol.
15:1974-1982[Abstract].
|
| 32.
|
Miller, A. D., and G. J. Rosman.
1989.
Improved retroviral vectors for gene transfer and expression.
BioTechniques
7:980-986[Medline], 989.
|
| 33.
|
Moazed, D., and D. Johnson.
1996.
A deubiquitinating enzyme interacts with SIR4 and regulates silencing in S. cerevisiae.
Cell
86:667-677[Medline].
|
| 34.
|
Okuda, T.,
Z. Cai,
S. Yang,
N. Lenny,
C. Lyu,
D. J. Van,
H. Harada, and J. R. Downing.
1998.
Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors.
Blood
91:3134-3143[Abstract/Free Full Text].
|
| 35.
|
Okuda, T.,
D. J. Van,
S. W. Hiebert,
G. Grosveld, and J. R. Downing.
1996.
AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.
Cell
84:321-330[Medline].
|
| 36.
|
Onno, M.,
T. Nakamura,
R. Mariage-Samson,
J. Hillova, and M. Hill.
1993.
Human TRE17 oncogene is generated from a family of homologous polymorphic sequences by single-base changes.
DNA Cell Biol.
12:107-118[Medline].
|
| 37.
|
Palis, J., and P. D. Kingsley.
1995.
Differential gene expression during early murine yolk sac development.
Mol. Reprod. Dev.
42:19-27[Medline].
|
| 38.
|
Papa, F. R., and M. Hochstrasser.
1993.
The yeast DOA4 gene encodes a deubiquitinating enzyme related to a product of the human tre-2 oncogene.
Nature
366:313-319[Medline].
|
| 39.
|
Pardee, A. B.
1989.
G1 events and regulation of cell proliferation.
Science
246:603-608[Abstract/Free Full Text].
|
| 40.
|
Rhoades, K. L.,
C. J. Hetherington,
J. D. Rowley,
S. W. Hiebert,
G. Nucifora,
D. G. Tenen, and D. E. Zhang.
1996.
Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis.
Proc. Natl. Acad. Sci. USA
93:11895-11900[Abstract/Free Full Text].
|
| 41.
|
Rock, K. L.,
C. Gramm,
L. Rothstein,
K. Clark,
R. Stein,
L. Dick,
D. Hwang, and A. L. Goldberg.
1994.
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.
Cell
78:761-771[Medline].
|
| 42.
|
Rowley, J. D.
1990.
Recurring chromosome abnormalities in leukemia and lymphoma.
Semin. Hematol.
27:122-136[Medline].
|
| 43.
|
Scheffner, M.,
J. M. Huibregtse,
R. D. Vierstra, and P. M. Howley.
1993.
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.
Cell
75:495-505[Medline].
|
| 44.
|
Svedberg, H.,
K. Chylicki,
B. Baldetorp,
F. J. Rauscher, and U. Gullberg.
1998.
Constitutive expression of the Wilm's tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program.
Oncogene
16:925-932[Medline].
|
| 45.
|
Tobias, J. W., and A. Varshavsky.
1991.
Cloning and functional analysis of the ubiquitin-specific protease gene UBP1 of Saccharomyces cerevisiae.
J. Biol. Chem.
266:12021-12028[Abstract/Free Full Text].
|
| 46.
|
Valtieri, M.,
D. J. Tweardy,
D. Caracciolo,
K. Johnson,
F. Mavilio,
S. Altmann,
D. Santoli, and G. Rovera.
1987.
Cytokine-dependent granulocytic differentiation. Regulation of proliferative and differentiative responses in a murine progenitor cell line.
J. Immunol.
138:3829-3835[Abstract].
|
| 47.
|
Vassilev, A. P.,
H. H. Rasmussen,
E. I. Christensen,
S. Nielsen, and J. E. Celis.
1995.
The levels of ubiquitinated histone H2A are highly upregulated in transformed human cells: partial colocalization of uH2A clusters and PCNA/cyclin foci in a fraction of cells in S-phase.
J. Cell Sci.
108:1205-1215[Abstract].
|
| 48.
|
Verma, I. M.,
J. K. Stevenson,
E. M. Schwartz,
A. D. Van, and S. Miyamoto.
1995.
Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation.
Genes Dev.
9:2723-2735[Free Full Text].
|
| 49.
|
Wang, Q.,
T. Stacy,
M. Binder,
M. Marin-Padilla,
A. H. Sharpe, and N. A. Speck.
1996.
Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis.
Proc. Natl. Acad. Sci. USA
93:3444-3449[Abstract/Free Full Text].
|
| 50.
|
Wang, Y.,
Y. G. Yeung,
W. Y. Langdon, and E. R. Stanley.
1996.
c-Cbl is transiently tyrosine-phosphorylated, ubiquitinated, and membrane-targeted following CSF-1 stimulation of macrophages.
J. Biol. Chem.
271:17-20[Abstract/Free Full Text].
|
| 51.
|
Wilkinson, K. D.,
V. L. Tashayev,
L. B. O'Connor,
C. N. Larsen,
E. Kasperek, and C. M. Pickart.
1995.
Metabolism of the polyubiquitin degradation signal: structure, mechanism, and role of isopeptidase T.
Biochemistry
34:14535-14546[Medline].
|
| 52.
|
Yaglom, J.,
M. H. K. Linskens,
S. Sadis,
D. M. Rubin,
B. Futcher, and D. Finley.
1995.
p34Cdc28-mediated control of Cln3 cyclin degradation.
Mol. Cell. Biol.
15:731-741[Abstract].
|
| 53.
|
Yergeau, D. A.,
C. J. Hetherington,
Q. Wang,
P. Zhang,
A. H. Sharpe,
M. Binder,
M. Marin-Padilla,
D. G. Tenen,
N. A. Speck, and D. E. Zhang.
1997.
Embryonic lethality and impairment of haemotopoiesis in mice heterozygous for an AML1-ETO fusion gene.
Nat. Genet.
15:303-306[Medline].
|
| 54.
|
Zhu, Y.,
M. Carroll,
F. R. Papa,
M. Hochstrasser, and A. D. D'Andrea.
1996.
DUB-1, a deubiquitinating enzyme with growth-suppressing activity.
Proc. Natl. Acad. Sci. USA
93:3275-3279[Abstract/Free Full Text].
|
| 55.
|
Zhu, Y.,
K. Lambert,
C. Corless,
N. G. Copeland,
D. J. Gilbert,
N. A. Jenkins, and A. D. D'Andrea.
1997.
DUB-2 is a member of a novel family of cytokine-inducible deubiquitinating enzymes.
J. Biol. Chem.
272:51-57[Abstract/Free Full Text].
|
Molecular and Cellular Biology, April 1999, p. 3029-3038, Vol. 19, No. 4
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.